Avacta Group PLC (DE:RTQ1)
FRANKFURT:RTQ1
Earnings Data
Report Date
Oct 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.05Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple important positive developments: on-time clinical execution (first-in-human dosing for AVA6103), promising preclinical metrics (up to ~40x tumor Cmax and ~3x tumor selectivity), strengthened IP, focused R&D investment (+31.5% YoY), cost reductions and a successful recent fundraising that extends runway into early Q1 2027. Offsetting these positives are meaningful near-term financing and timeline risks — limited cash runway without partner income, dependence on partnership to launch pivotal studies, tolerability/dose-selection questions at higher AVA6000 doses, and delays/hold status for the Affimer program. On balance the call emphasized substantive scientific and clinical progress alongside manageable but material financing and timing risks.Company Guidance
Clinical Milestone — AVA6103 First Patient Dosed
First patient dosed in FOCUS-01 Phase I (AVA6103) on time in March 2026; multicenter US-focused trial enrolling 6 advanced cancers with initial clinical data committed by end of 2026 (late Q4).
Encouraging AVA6000 Clinical Progress and Regulatory Outcome
AVA6000 (Gen One) reported preliminary efficacy and safety in salivary gland cancer; Phase Ib continues with a recommended dose for expansion (RDE) defined at 310 mg/m2; favorable cardiac safety data resulted in lifting of the lifetime maximum doxorubicin dose constraint.
Strong Preclinical Differentiation vs ADCs
Preclinical translational data show up to ~40x higher tumor Cmax for released exatecan (AVA6103) versus comparator ADC payloads and ~3x higher tumor selectivity index (tumor vs plasma) — key mechanistic advantages that may translate clinically.
Increased R&D Investment Reflecting Pipeline Focus
Research & development spend rose to GBP 18.8m in FY2025 from GBP 14.3m prior year, a ~31.5% increase, reflecting focused investment in the proprietary pre|CISION peptide drug conjugate platform and therapeutic programs.
Improved Cost Efficiency in Administration and Cash Outflows
Administrative expenses fell to ~GBP 10m from GBP 12m (~16.7% reduction). Net operating cash outflows improved to GBP 22.64m from GBP 24.94m (~9.2% reduction year-on-year).
Fundraising and Cash Position
Raised GBP 32.5m over the last 18 months (including an oversubscribed placing/subscription of GBP 10m); cash at end-April 2026 was GBP 16.4m, extending runway into early Q1 2027 (projection excludes partnering income).
Pipeline & IP Expansion — Gen Two and Gen Three Progress
Updated in vivo data for Gen Two (AVA6103) and Gen Three (AVA6207 dual-payload) at AACR; continued growth of IP estate protecting sustained release and dual-payload technologies; dual-payload capability is a novel differentiator.
DE:RTQ1 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:RTQ1 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 19, 2026 | €0.97 | €0.99 | +2.05% |
Sep 30, 2025 | €0.62 | €0.58 | -6.45% |
Jun 06, 2025 | €0.41 | €0.40 | -2.94% |
Sep 30, 2024 | €0.53 | €0.54 | +1.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Avacta Group PLC (DE:RTQ1) report earnings?
Avacta Group PLC (DE:RTQ1) is schdueled to report earning on Oct 05, 2026, Before Open (Confirmed).
What is Avacta Group PLC (DE:RTQ1) earnings time?
Avacta Group PLC (DE:RTQ1) earnings time is at Oct 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Avacta Group PLC stock?
The P/E ratio of Avacta Group plc is N/A.
What is DE:RTQ1 EPS forecast?
Currently, no data Available